The biggest winners, hands down, in the Canadian cannabis supply shortage are all of the smaller, later-to-market producers. It buys them time to get to market, and it will take longer for the first wave of suppliers who are already in stores to build up the brand loyalty they were counting on.
There are still riches to be made from medical cannabis. Maryland showed it this month by smashing annual estimates for sales. And a New York company just made almost $50 million by selling its license before ever selling any actual marijuana.
Epidolex may be the first FDA-approved, cannabis-based pharma product on the market. But over-the-counter, hemp-based CBD products will take a large bite out of that market as it continues to show similar effects as the price, prescription-based brand.
New Jersey will be bring in recreational cannabis money at the register by 2019 - others will follow. That's why the East Coast is becoming the market to watch and could surpass California's market size.
Not all IPOs are created equal. The biggest winners, the next Tilray, are going to thrive in at least one of three key areas of focus. These are areas where companies can truly differentiate themselves from the crowd.
Doctors, researchers, veterans who use cannabis, and a prominent professional athlete talk to the National Institute for Cannabis Investors about PTSD and how much cannabis-based products can help in treating the disease.
It's difficult to see a stock you recently bought go down. But as those who sold during Canopy Growth's three significant declines dating back to 2015 would attest, now is not the time to lose our resolve.